Equity Overview
Price & Market Data
Price: $1.37
Daily Change: -$0.05 / 3.65%
Range: $1.36 - $1.43
Market Cap: $160,081,760
Volume: 149,481
Performance Metrics
1 Week: -3.52%
1 Month: -12.74%
3 Months: %
6 Months: 34.31%
1 Year: 37.00%
YTD: 96.78%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United Kingdom
Details
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.